[Skip to Content]
[Skip to Content Landing]
Views 40
Citations 0
Comment & Response
November 28, 2018

High-Density Lipoprotein–Targeted Therapies—Not Dead Yet—Reply

Author Affiliations
  • 1South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, South Australia, Australia
  • 2Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
JAMA Cardiol. Published online November 28, 2018. doi:10.1001/jamacardio.2018.3973

In Reply We read with interest the letter by Garcia-Ropero et al in response to our report of the MDCO-216 Infusions Leading to Changes in Atherosclerosis: a Novel Therapy in Development to Improve Cardiovascular Outcomes—Proof of Concept IVUS, Lipids, and Other Surrogate Biomarkers (MILANO-PILOT) study.1 In our article, we reported that intravenous infusions of a high-density lipoprotein (HDL) mimetic containing recombinant apolipoprotein A-I Milano did not produce incremental regression of coronary atherosclerosis in patients treated with high-intensity statins following an acute coronary syndrome. We concluded that the findings continue to fuel skepticism regarding the clinical utility of HDL-targeted therapies.1